このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

2026年7月30日 更新者:Livzon Pharmaceutical Group Inc.

A Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis

This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

244

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Shanghai、中国
        • Shanghai Dermatology Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Aged ≥18 years at screening, male or female.
  2. History of psoriasis for ≥6 months prior to screening, diagnosed as plaque psoriasis according to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 Edition) at screening, and considered by the investigator to be suitable for systemic therapy.
  3. Meeting all three of the following criteria at screening:

    (A)PASI score ≥10;

    (B)sPGA score ≥3;

    (C)BSA ≥10%.

  4. Female participants of childbearing potential must agree to have no pregnancy or egg donation from the time of signing the informed consent form to the end of the study, and voluntarily use highly effective contraceptive measures, except for postmenopausal women; male participants must agree to have no pregnancy (of partner) or sperm donation from the time of signing the informed consent form to the end of the study, and voluntarily use highly effective contraceptive measures. Menopause is defined as meeting one of the following: a) history of bilateral oophorectomy or hysterectomy; b) age ≥55 years, with amenorrhea for ≥12 months without other pathological or physiological reasons; c) age <55 years, with amenorrhea for ≥12 months without other pathological or physiological reasons, and estradiol (E2) <20 pg/mL or follicle-stimulating hormone (FSH) >40 mIU/mL.
  5. Ability to understand and comply with the protocol requirements, and voluntary participation in the clinical trial.

Exclusion Criteria:

  1. History of severe allergic reaction to biological agents, or previous history of severe drug allergy.
  2. Presence of inflammation, ulceration, induration, scar, mass, or other conditions at the injection site that, in the investigator's opinion, preclude subcutaneous injection administration.
  3. Presence of other types of psoriasis at screening, including but not limited to erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, drug-induced psoriasis (including new onset or exacerbation of psoriasis caused by β-blockers, non-steroidal anti-inflammatory drugs, antimalarials, interferons, calcium channel blockers, or lithium).
  4. Presence of severe skin infection, eczema, seborrheic dermatitis, neurodermatitis, or other skin conditions at screening that, in the investigator's assessment, may interfere with the evaluation of psoriasis treatment efficacy.
  5. Meeting any of the following conditions:

    (A)Diagnosed with active tuberculosis infection, including but not limited to active tuberculosis confirmed by imaging;

    (B)Latent tuberculosis infection or close contact with a tuberculosis patient, except in the following cases: a) confirmed by a specialist that standard treatment for latent tuberculosis infection has been completed within 5 years prior to the first dose; b) prophylactic anti-tuberculosis treatment has been initiated at least 4 weeks before the first dose and the subject is willing to continue prophylaxis according to local guidelines; c) the specialist judges that the risk of progression to active tuberculosis is low and that treatment is not required.

    Latent tuberculosis infection is defined as: positive interferon-gamma release assay (IGRA) at screening, without any clinical signs or symptoms of active tuberculosis. Close contact with a tuberculosis patient is defined as: having had close contact (i.e., spending several days or weeks together in a relatively enclosed space) with a patient with active pulmonary tuberculosis within the past 12 months, or having a family member diagnosed with active tuberculosis infection.

  6. History of severe immunodeficiency, including: positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases.
  7. Presence of any of the following clinically significant conditions:

    (A)History of chronic congestive heart failure with NYHA Class IV; history of echocardiographic cardiac ejection fraction (EF) below 30%;

    (B)Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months prior to screening; coronary revascularization within 6 months prior to screening;

    (C)History of severe arrhythmias requiring treatment with Class Ia or Class III antiarrhythmic drugs; history of sick sinus syndrome, second-degree type II or third-degree atrioventricular block without an implanted pacemaker;

    (D)Screening ECG showing QTc interval ≥480 ms (Fridericia correction formula, QTc = QT/(RR^0.33)), or history of prolonged QTc interval and assessed by the investigator as having arrhythmia risk;

    (E)Poorly controlled hypertension within 3 months prior to screening (poorly controlled defined as: blood pressure still not reaching target despite combination therapy with ≥3 antihypertensive agents), or screening systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed by repeated measurements;

    (F)History of severe psychiatric disorders such as depression, schizophrenia, schizoaffective disorder, or history of suicidal ideation or suicidal behavior;

    (G)History of severe neurological disorders such as stroke or epilepsy;

    (H)Active bleeding disorders of internal organs, or severe bleeding tendency (e.g., hemophilia);

    (I)Other progressive or uncontrolled systemic diseases that, in the investigator's assessment, may be unstable or may become severe during the trial, making the subject unsuitable for participation.

  8. Meeting either of the following: a) any severe infection within 1 month prior to screening (defined as infection requiring hospitalization or intravenous anti-infective treatment); b) history of opportunistic infections or recurrent, chronic infections that, in the investigator's opinion, could lead to study discontinuation. Opportunistic infections include infections caused by unusual pathogens (e.g., Pneumocystis jirovecii, cryptococcus, etc.) or unusually severe infections caused by common pathogens (e.g., cytomegalovirus, herpes virus, etc.).
  9. History of cancer within 5 years prior to screening, except for cured cutaneous basal cell carcinoma or Stage I squamous cell carcinoma.
  10. History of alcohol abuse (defined as consumption of 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine) or history of illicit drug use within 1 year prior to screening.
  11. Presence of active autoimmune diseases other than psoriasis or psoriatic arthritis (e.g., inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, inflammatory myopathies, mixed connective tissue disease, overlap syndrome, etc.).
  12. Use of topical anti-psoriatic drugs or physical therapy within 2 weeks prior to screening (see prohibited medications/therapies for details).
  13. Use of systemic anti-psoriatic drugs other than biologics within 4 weeks prior to screening (see prohibited medications for details).
  14. Use of TNF-α inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, or IL-17 inhibitors within 3 months or 5 half-lives (whichever is longer) prior to screening (see prohibited medications for details).
  15. Previous participation in and receipt of study drug in the LZM012 clinical trial.
  16. Participation in any clinical trial of an investigational drug (defined as having received study drug) within 3 months or 5 half-lives of the investigational drug (whichever is longer) prior to screening.
  17. Any of the following laboratory results at screening:

    (A)Hematology: hemoglobin (HGB) <90 g/L; platelet count (PLT) <100 × 10⁹/L; white blood cell count (WBC) <3 × 10⁹/L; absolute neutrophil count (NEUT) <1.5 × 10⁹/L;

    (B)Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >1.5 times ULN;

    (C)Renal function: serum creatinine >1.5 times ULN.

  18. Receipt of a live vaccine (including attenuated live vaccine) within 3 months prior to screening, or planned receipt of a live vaccine (including attenuated live vaccine) during the trial.
  19. Meeting any of the following at screening:

    (A)Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with further testing showing HBV-DNA ≥500 IU/mL;

    (B)Positive hepatitis C virus (HCV) antibody with further testing showing HCV RNA positive;

    (C)Positive syphilis specific antibody with further testing showing positive syphilis non-specific antibody (including but not limited to rapid plasma reagin (RPR) test, toluidine red unheated serum test (TRUST), etc.).

  20. Pregnant or breastfeeding women, or positive pregnancy test result at screening.
  21. Any other condition or situation that, in the investigator's opinion, makes the subject unsuitable for participation in this trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:LZM012 Monotherapy Group
320mg LZM012 subcutaneous injection every 4 weeks for 3 doses, no dose adjustment permitted.
組換え抗ヒトIL-17A/Fヒト化モノクローナル抗体注射剤

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
PASI100応答率
時間枠:12週目
PASI100に達した患者の割合(PASI100奏効率)
12週目

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to first achievement of PASI50, PASI75, PASI90 and PASI100
時間枠:Up to Week 12
Up to Week 12
PASI75/PASI90 response rate
時間枠:At week 4、 At week 8、 At week 12
At week 4、 At week 8、 At week 12
Absolute and relative percentage change from baseline in PASI score at each visit
時間枠:at Week 4, Week 8, Week 12
at Week 4, Week 8, Week 12
sPGA 0/1 response rate
時間枠:At week 4、 At week 8、 At week 12
At week 4、 At week 8、 At week 12
change in Dermatology Life Quality Index (DLQI) score
時間枠:At week 4、 At week 8、 At week 12
Dermatology Life Quality Index (DLQI) Score range: 0 to 30; higher scores indicate worse health-related quality of life.
At week 4、 At week 8、 At week 12
treatment-emergent adverse events
時間枠:up to week 16
up to week 16
Vital signs: systolic blood pressure
時間枠:Up to Week 16
Up to Week 16
Vital signs: diastolic blood pressure
時間枠:Up to Week 16
Up to Week 16
Vital signs: pulse rate
時間枠:up to week 16
up to week 16
Vital signs: tympanic temperature
時間枠:up to week 16
up to week 16
Electrocardiogram (ECG): PR interval, QT interval
時間枠:Up to Week 16
Up to Week 16
Electrocardiogram (ECG): heart rate
時間枠:up to week 16
up to week 16
physical examinatio: Proportion of subjects with abnormal skin findings on physical examination
時間枠:Up to Week 16
Up to Week 16
physical examination:Proportion of subjects with abnormal head and neck findings on physical examination
時間枠:up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal chest findings on physical examination
時間枠:up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal abdomen findings on physical examination
時間枠:up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal extremities findings on physical examination
時間枠:up to week 16
up to week 16
Incidence of anti-drug antibody (ADA) and neutralizing antibody (NAb) positive
時間枠:From baseline to Week 12
From baseline to Week 12
Laboratory tests: hematology:Platelet count, Neutrophil count, Lymphocyte count, White blood cell (WBC) count
時間枠:up to week 16
up to week 16
Laboratory tests: hematology:Hemoglobin (Hb)
時間枠:up to week 16
up to week 16
Laboratory tests: hematology:Hematocrit (Hct), Neutrophil percentage
時間枠:up to week 16
up to week 16
Laboratory tests: serum biochemistry:Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Creatine phosphokinase (CPK)
時間枠:up to week 16
up to week 16
Laboratory tests: serum biochemistry:Total bilirubin (TBIL), Direct bilirubin (DBIL), Creatinine (Cr), Uric acid (UA);
時間枠:up to week 16
up to week 16
Laboratory tests: serum biochemistry:Total cholesterol (TC), Triglycerides (TG), Low-density lipoprotein cholesterol (LDL-C), Glucose (GLU)
時間枠:up to week 16
up to week 16
Laboratory tests: urinalysis:Urine protein, urine glucose, urine ketone bodies;
時間枠:up to week 16
up to week 16
Laboratory tests: urinalysis:Urine leukocytes, urine erythrocytes
時間枠:up to week 16
up to week 16

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月23日

一次修了 (実際)

2026年1月26日

研究の完了 (実際)

2026年1月26日

試験登録日

最初に提出

2026年7月8日

QC基準を満たした最初の提出物

2026年7月30日

最初の投稿 (実際)

2026年8月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月5日

QC基準を満たした最後の更新が送信されました

2026年7月30日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • LZM012-302

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する